Savara MOLBREEVI MAA Accepted by UK MHRA for PAP
Langhorne, Pennsylvania, USA, April 7, 2026 MHRA Acceptance Marks Key Regulatory Milestone In a significant advancement for rare disease...
MHRA
Advertisement
OS Therapies Advances OST-HER2 Toward FDA Approval
NEW YORK, March 31, 2026 — OS Therapies, Inc a clinical-stage oncology company specializing in listeria-based cancer immunotherapies, has...
OS Therapies Advances OST-HER2 Toward Phase 3 Trial
New York, March 27, 2026 OS Therapies has achieved a significant regulatory milestone by securing meetings with multiple global...
Tangram Advances TGM-312 With Phase 1/2 CTA Submission
LONDON — November 26, 2025. Tangram Therapeutics has submitted a Clinical Trial Application (CTA) to the UK Medicines and...
OS Therapies Reports 75% Two-Year Survival in Osteosarcoma Immunotherapy Trial
New York, NY – October 10, 2025 – OS Therapies Inc. has announced statistically significant positive final results from...
Advertisement
